Citations

Clear

79 citation(s) found for "Stricker".

Methods for alerting clinicians to concerning symptom questionnaire responses during cancer care: Approaches from two randomized trials (STAR, AFT-39 PRO-TECT).
Henson, Sydney, Deal, Allison M. , Hammelef, Karen, Carr, Philip, Jansen, Jennifer , Kottschade, Lisa A. , Basch, Ethan , Stover, Angela M , Deal, Allison , Stricker, Carrie Tompkins , Bennett, Antonia V , Jansen, Jennifer , Dueck, Amylou C. , Basch, Ethan

Mayo Clinic

Journal of Clinical Oncology | September 25, 2018 | Volume: 36 | Issue: 30_suppl | Pages: 158-158

10.1200/jco.2018.36.30_suppl.158 Get It

158 Background: There is limited research on methods for alerting clinicians to concerning patient-reported outcome (PRO) responses and how often PROs trigger alerts to nurses during cancer care. Methods: In two randomized trials, adults with advanced cancer receiving chemotherapy were enrolled. Participants were randomized to usual care vs. weekly PROs completed between visits (with automated feedback to nurses). PRO responses in the intervention arm triggered automated email alerts to nurses for frequent, severe, or worsening symptoms in the last 7 days. Alert thresholds for PROs were chosen a priori but were unique to each study. The “Symptom Tracking and Reporting” (STAR) trial was conducted at one academic medical center. The “PROs to Enhance Cancer Treatment” (PRO-TECT [AFT-39]) cluster-randomized trial is being conducted in > 30 community practices. Results: In STAR, 766 patients participated (58% female, 38% ages ≥65, 17% minority, 28% ≤high school). 441 participants were randomized to the intervention arm, where 1,431/84,212 items (2%) triggered a concerning symptom alert, during 1,070/8,498 weeks (13%). Frequent alerts were for fatigue (62%), pain (32%), and appetite (16%). In PRO-TECT (AFT-39), 300 patients have been enrolled (58% female, 49% ages ≥65, 8% minority, 47% ≤high school) out of 1,000. 146 participants have been randomized to the intervention arm, where 1,422/24,739 items (6%) triggered an alert, during 824/2249 weeks (37%). Common alerts were for pain (48%), physical function (35%), and diarrhea (15%). PRO-TECT provided clinical decision support with alerts. Conclusions: In two randomized trials in advanced cancer, PROs collected during care delivery enabled tailored treatment based on issues identified on PROs. Pain, physical function, appetite, and diarrhea commonly triggered alerts for concerning symptoms. Early PRO-TECT results are showing a trend for higher weekly alert rates for concerning symptoms (37% vs. 13% in STAR), which may indicate that the PRO intervention will be even more effective in community practices. Results assist in addressing logistical considerations for implementing PROs into routine care. Clinical trial information: NCT03249090.
A comprehensive evaluation of the genetic architecture of sudden cardiac arrest
Ashar, Foram N., Albert, Christine M. , Newton‐Cheh, Christopher , Brody, Jennifer A. , Müller‐Nurasyid, Martina , Moes, Anna, Huikuri, Heikki V. , Junttila, Juhani , Goyette, Philippe, Pazoki, Raha , Tanck, Michael W.T. , Blom, Marieke T. , Jabbari, Reza , Glinge, Charlotte , Tragante, Vinicius , Escher, Stefan Andersson, Chakravarti, Aravinda , Ehret, Georg , Li, Man , Prineas, Ronald J. , Franco, Oscar H. , Lumley, Thomas, Dumas, Florence , McKnight, Barbara, Rotter, Jerome I. , Heckbert, Susan R. , O’Donnell, Christopher J., VanDenburgh, Martin, Uitterlinden, André G. , Hofman, Albert , Stricker, Bruno H. , Bakker, Paul I. W. de , Franks, Paul W. , Jansson, Jan‐Håkan , Asselbergs, Folkert W. , Maleszewski, Joseph J. , Tfelt‐Hansen, Jacob , Kolodgie, Frank D. , Wilde, Arthur A.M. , Bezzina, Connie R. , Eijgelsheim, Mark, Rioux, John D. , Jouven, Xavier , Arking, Dan E. , Sotoodehnia, Nona , Tanck, Michael , Tfelt-Hansen, Jacob , Rotter, Jerome I , Brody, Jennifer A , Bezzina, Connie R , Mitchell, Rebecca N, Meitinger, Thomas , Mak, Angel C. Y. , Pulit, Sara L. , Zhao, Xiaoqing , Havulinna, Aki Samuli , Coresh, Josef , Kwok, Pui–Yan , Lemaître, Rozenn N. , Hwang, Shih‐Jen , Tardif, Jean‐Claude , Halushka, Marc K. , Engstrøm, Thomas , Salomaa, Veikko , Virmani, Renu , Tan, Hanno L. , Kääb, Stefan , Psaty, Bruce M. , Siscovick, David S. , Rioux, John D , Albert, Christine M.

Mayo Clinic

European Heart Journal | July 20, 2018 | Volume: 39 | Issue: 44 | Pages: 3961-3969

10.1093/eurheartj/ehy474 | PMID 30169657 Get It

[P1–473]: DOES PERFORMANCE ON COGSTATE VARY LONGITUDINALLY ACROSS DIFFERENT MODES OF ADMINISTRATION?
Edwards, Kelly K., Roberts, Rosebud O., Petersen, Ronald C. , Stricker, Nikki H. , Lundt, Emily S. , Machulda, Mary M. , Knopman, David S. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_9 | Pages: No page available

10.1016/j.jalz.2017.06.489 Get It

[P3–455]: DETECTABLE NEUROPSYCHOLOGICAL DIFFERENCES IN EARLY PRECLINICAL ALZHEIMER's DISEASE: A META‐ANALYSIS
Han, Duke, Nguyen, Caroline, Nation, Daniel A. , Stricker, Nikki H.

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_23 | Pages: No page available

10.1016/j.jalz.2017.06.1673 Get It

Taxonomy for Education and Training in Clinical Neuropsychology : past, present, and future
Sperling, Scott A. , Cimino, Cynthia R., Stricker, Nikki H. , Heffelfinger, Amy , Gess, Jennifer L. , Osborn, Katie E. , Roper, Brad L. , Stricker, Nikki H , Sperling, Scott , Heffelfinger, Amy

Mayo Clinic

The Clinical Neuropsychologist | April 10, 2017 | Volume: 31 | Issue: 5 | Pages: 817-828

10.1080/13854046.2017.1314017 | PMID 28391739 Get It

Elevated rates of memory impairment in military service-members and veterans with posttraumatic stress disorder
Stricker, Nikki H. , Lippa, Sara M. , Green, Deborah L., McGlynn, Susan M., Grande, Laura, McGlinchey, Regina E. , Milberg, William P , Stricker, Nikki H

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | December 18, 2016 | Volume: 39 | Issue: 8 | Pages: 768-785

10.1080/13803395.2016.1264575 | PMID 27976973 Get It

Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE‐AF Consortium
Alonso, Álvaro , Krijthe, Bouwe P., Aspelund, Thor , Stepas, Katherine A., Pencina, Michael , Moser, Carlee , Sinner, Moritz F. , Sotoodehnia, Nona, Fontes, João D. , Janssens, A. Cecile J.W. , Witteman, Jacqueline C.M., Chamberlain, Alanna M. , Lubitz, Steven A. , Agarwal, Sunil , McManus, David D. , Ellinor, Patrick T. , Larson, Martin G. , Burke, Gregory L. , Hofman, Albert , Levy, Daniel , Gottdiener, John S. , Couper, David , Harris, Tamara B. , Soliman, Elsayed Z. , Stricker, Bruno H. , Guðnason, Vilmundur , Heckbert, Susan R. , Benjamin, Emelia J. , Kronmal, Richard A. , Magnani, Jared W. , Schnabel, Renate B. , Launer, Lenore J. , Kääb, Stefan , Alonso, Alvaro , Chamberlain, Alanna M , Benjamin, Emelia J , Lubitz, Steven A , Ellinor, Patrick T , Levy, Daniel , Couper, David

Mayo Clinic

Journal of the American Heart Association | May 24, 2013 | Volume: 2 | Issue: 2 | Pages: No page available

10.1161/jaha.112.000102 | PMID 23537808 Get It

Background Tools for the prediction of atrial fibrillation ( AF ) may identify high‐risk individuals more likely to benefit from preventive interventions and serve as a benchmark to test novel putative risk factors. Methods and Results Individual‐level data from 3 large cohorts in the U nited S tates (Atherosclerosis Risk in Communities [ ARIC ] study, the Cardiovascular Health Study [ CHS ], and the Framingham Heart Study [ FHS ]), including 18 556 men and women aged 46 to 94 years (19% A frican A mericans, 81% whites) were pooled to derive predictive models for AF using clinical variables. Validation of the derived models was performed in 7672 participants from the Age, Gene and Environment—Reykjavik study ( AGES ) and the Rotterdam Study ( RS ). The analysis included 1186 incident AF cases in the derivation cohorts and 585 in the validation cohorts. A simple 5‐year predictive model including the variables age, race, height, weight, systolic and diastolic blood pressure, current smoking, use of antihypertensive medication, diabetes, and history of myocardial infarction and heart failure had good discrimination (C‐statistic, 0.765; 95% CI , 0.748 to 0.781). Addition of variables from the electrocardiogram did not improve the overall model discrimination (C‐statistic, 0.767; 95% CI , 0.750 to 0.783; categorical net reclassification improvement, −0.0032; 95% CI , −0.0178 to 0.0113). In the validation cohorts, discrimination was acceptable ( AGES C‐statistic, 0.664; 95% CI , 0.632 to 0.697 and RS C‐statistic, 0.705; 95% CI , 0.664 to 0.747) and calibration was adequate. Conclusion A risk model including variables readily available in primary care settings adequately predicted AF in diverse populations from the U nited S tates and E urope.
A Genome‐Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium
Tang, Weihong , Heit, John A. , Morange, Pierre‐Emmanuel , Pankratz, Nathan , Leebeek, Frank W.G. , Paré, Guillaume , Tzourio, Christophe , Basu, Saonli , Rose, Lynda M., Armasu, Sebastian M. , Lumley, Thomas, Heckbert, Susan R. , Uitterlinden, André G. , Lathrop, Mark, Cushman, Mary , Hofman, Albert , Lambert, Jean‐Charles , Glazer, Nicole L. , Pankow, James S. , Witteman, Jacqueline C.M., Amouyel, Philippe , Bis, Joshua C. , Bovill, Edwin G., Kong, Xiaoxiao , Boerwinkle, Eric , Trégouët, David‐Alexandre , Loth, Daan W. , Stricker, Bruno H. , Folsom, Aaron R. , Smith, Nicholas L. , Teichert, Martina , Chasman, Daniel I. , Guo, Li , Andrade, Mariza de , Psaty, Bruce M. , Ruiter, Rikje , Rice, Kenneth , Tracy, Russell P. , Rotter, Jerome I. , Ridker, Paul M. , Amouyel, Philippe , Tzourio, Christophe , Pankratz, Nathan , Pankow, James S , Tang, Weihong , Paré, Guillaume

Mayo Clinic

Genetic Epidemiology | May 5, 2013 | Volume: 37 | Issue: 5 | Pages: 512-521

10.1002/gepi.21731 | PMID 23650146 Get It

ABSTRACTVenous thromboembolism (VTE) is a common, heritable disease resulting in high rates of hospitalization and mortality. Yet few associations between VTE and genetic variants, all in the coagulation pathway, have been established. To identify additional genetic determinants of VTE, we conducted a two‐stage genome‐wide association study (GWAS) among individuals of European ancestry in the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) VTE consortium. The discovery GWAS comprised 1,618 incident VTE cases out of 44,499 participants from six community‐based studies. Genotypes for genome‐wide single‐nucleotide polymorphisms (SNPs) were imputed to approximately 2.5 million SNPs in HapMap and association with VTE assessed using study‐design appropriate regression methods. Meta‐analysis of these results identified two known loci, in F5 and ABO. Top 1,047 tag SNPs (P ≤ 0.0016) from the discovery GWAS were tested for association in an additional 3,231 cases and 3,536 controls from three case‐control studies. In the combined data from these two stages, additional genome‐wide significant associations were observed on 4q35 at F11 (top SNP rs4253399, intronic to F11) and on 4q28 at FGG (rs6536024, 9.7 kb from FGG; P < 5.0 × 10−13 for both). The associations at the FGG locus were not completely explained by previously reported variants. Loci at or near SUSD1 and OTUD7A showed borderline yet novel associations (P < 5.0 × 10−6) and constitute new candidate genes. In conclusion, this large GWAS replicated key genetic associations in F5 and ABO, and confirmed the importance of F11 and FGG loci for VTE. Future studies are warranted to better characterize the associations with F11 and FGG and to replicate the new candidate associations.